Synapse - Brian Ball

Results (17)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Journal Article

McCarter, J. G. W.; Nemirovsky, D.; Famulare, C. A.; Farnoud, N.; Mohanty, A. S.; Stone-Molloy, Z. S.; Chervin, J.; Ball, B. J.; Epstein-Peterson, Z. D.; Arcila, M. E.; more...
Blood Advances (2023)

Fulltext@MSK | Save

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Research Letter

Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
Blood (2023)

Fulltext@MSK | Save

Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)

Meeting Abstract

Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

Journal Article

Komrokji, R.; Melody, M.; al Ali, N.; Chan, O.; Klimek, V.; Ball, B. J.; Sekeres, M. A.; Lucas, G.; Maciejewski, J. P.; Sallman, D. A.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis

Meeting Abstract

Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
Blood (2021)

Fulltext@MSK | Save

Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia

Meeting Abstract

Grenet, J.; Jain, A. G.; Burkart, M.; Waksal, J.; Famulare, C.; Numan, Y.; Stahl, M.; Mckinnell, Z.; Ball, B.; Ma, X.; more...
Blood (2021)

Fulltext@MSK | Save

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: Feasibility and preliminary efficacy of the Beat AML Master Trial

Research Letter

Burd, A.; Levine, R. L.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P.; Baer, M. R.; Stock, W.; Deininger, M.; more...
Nature Medicine (2020)

Fulltext@MSK | Save

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Journal Article

Ball, B. J.; Famulare, C. A.; Stein, E. M.; Tallman, M. S.; Derkach, A.; Roshal, M.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA